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Objective: Few epidemiological studies have addressed the health of workers
exposed to novel manufactured nanomaterials. The small current workforce
will necessitate pooling international cohorts. Method: A road map was de-
fined for a globally harmonized framework for the careful choice ofmaterials,
exposure characterization, identification of study populations, definition of
health endpoints, evaluation of appropriateness of study designs, data col-
lection and analysis, and interpretation of the results. Results: We propose a
road map to reach global consensus on these issues. The proposed strategy
should ensure that the costs of action are not disproportionate to the potential
benefits and that the approach is pragmatic and practical. Conclusions: We
should aim to go beyond the collection of health complaints, illness statistics,
or even counts of deaths; the manifestation of such clear endpoints would
indicate a failure of preventive measures.
WHY HARMONIZE WORLDWIDE?
Nanomaterials, because of their novel physicochemical prop-
erties, are making their way into businesses and products. After a
phase of “nano-hype” with few concrete nanomaterial applications,
development of real-life products and processes including nanomate-
rials is now progressing steadily. Already today, about 1% of all com-
panies are involved with nanomaterial production or development,1,2
although each of them has only a few workers actually dealing with
nanomaterials. Nevertheless, with the growing number of existing
and novel nanomaterials, their applications, and their incorpora-
tion in products, an increasing number of workers are expected to
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become exposed to these materials throughout the products’ life
cycles. In anticipation of this growing market, and in response to
debates about the potential health risks of nanomaterials, research
is being carried out worldwide in an effort to ensure that there are
no adverse health effects from working with nanomaterials.3 The
early identification of potential health and safety issues indeed al-
lows us to redirect investments for safer future steps in technology
development.
Most current research projects in this field focus on exposure
measurement techniques and toxicological research that identifies
mechanisms of effect and no adverse effect levels in test systems.4
Nevertheless, occupational health studies of exposed nanomaterial
workers are needed to confirm whether the derived levels are safe
and whether the applied safety and preventive health measures are
effective. Epidemiological studies of the health of workers producing
and using classic carbon black and amorphous silica nanomaterials
were carried out in the late 1980s and mid-1990s.5,6 Nevertheless,
the workforce in individual countries and companies1,7 is still small,
and there is a large diversity of nanomaterials, which poses chal-
lenges for the recruitment of sufficiently large cohorts. This leads to
the necessity for pooling cohorts internationally for consideration of
novel nanomaterials. The implementation of such studies is currently
hampered by (1) few standardized, accurate, and reliable approaches
for estimating exposure; (2) large variability in nanomaterial met-
rics and coexposures; (3) lack of information about health effects
and biomarkers; (4) lack of large production forces in this emerging
industry, rather a considerable proportion in research and develop-
ment; (5) questionable statistical power related to currently small
workforce sizes and short latency for disease occurrence; and (6)
a changing regulatory framework without harmonized registration
systems for workers used in these industries.8
Numerous different approaches could be adopted for mon-
itoring the health effects of nanomaterials, including occupational
health reporting schemes, health surveillance, health risk appraisal
surveys, and self-reporting questionnaires.3,9,10 Acceptability of dif-
ferent approaches will be strongly influenced by the social contexts
and regulatory backgrounds in different countries. These determine
where responsibilities lie and who ensures that the required steps in
both exposure assessment and health effect monitoring are imple-
mented.
In this report, the most pressing needs in terms of global
harmonization were identified as follows:
1. Outline the range of information necessary for epidemiological
studies of nanomaterial workers.
2. Evaluate exposure data and models useful for pooled exposure
assessments and provide task-based exposure profiles for specific
nanomaterials.
3. Link different worker activities and task profiles to job titles, job
descriptions, and industries on the one hand and to production
processes on the other.
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4. Evaluate health effects and biomarkers for use in future occupa-
tional health reporting schemes and epidemiological studies on
the basis of knowledge derived from toxicology studies of the
subject nanomaterial and inference from epidemiological studies
of other nanomaterials.
5. Define the requirements for epidemiological studies and identify
suitable cohorts.
6. Provide recommendations for small and medium enterprises and
associated organizations regarding early assessment and manage-
ment of possible risks for nanomaterial workers and the setup of
exposure and health effect registries.
Consequently, the rationale for creating this is that before
embarking on any large-scale, human health–monitoring studies, it
is of paramount importance to determine their feasibility andwhether
they will ensure useful, reliable results. Basic preparatory work is
thus needed to evaluate and analyze existing knowledge, data, and
practices for exposure and health effect assessment.
THE ROAD MAP DEVELOPMENT PROCEDURE
This road map is a product of expert discussions that started
in 2008 with the definition of the NanoImpactNet project plan (FP7-
Grant 218539, www.nanoimpactnet.eu). In 2009, during a NanoIm-
pactNet workshop in Lausanne, Switzerland, participants were asked
to answer a series of questions (Table 1) related to the design of oc-
cupational health surveillance studies for both short- and long-term
monitoring of the health of workers exposed to or handing nanoma-
terials.
The insight gained from the workshop was condensed into
a report,11 which was shared with the audience of a meeting orga-
nized by the National Institute for Occupational Safety and Health
(NIOSH) in Keystone, Colorado, in 2010.12 Realizing the potential
need for worldwide harmonization, a global group of World Health
Organization (WHO) Collaborating Centres and other partners was
formed to extend that report’s ideas to create this road map. The
road map presented here also will serve as a guide for nanomaterial-
related activities of the coauthoring researchers when preparing their
contributions to the implementation of the WHO Action Plan 2012–
2017.
THE ROAD MAP
The present road map proposes a strategy to gain global ac-
ceptability by many different actors for occupational health studies
in the field and to harmonize the collection and storage of data to
TABLE 1. Initial Questions About Issues That a Workers’
Health Surveillance Program Needs to Take Into Account
1. Assessing and recording exposure
a. How to gather qualitative and quantitative information on
exposure (nature of worker tasks, areas of workplaces, materials
being handled, control measures in place, field studies, etc)
b. How to record and access this information
2. Assessing and monitoring health or health surveillance
a. How to define a harmonized approach for data recording and
access
b. How to identify “effects” to be monitored, preferably early
markers of effect or indicators of biological response as opposed
to final outcome (disease and death)
3. Information dissemination
a. How to raise awareness among relevant health care professionals
b. How to disseminate the results of the monitoring to workers and
management
c. How to provide support to policymakers and other decision takers
yield maximum benefits for all the parties involved. It covers three
main domains: exposure, health, and framework conditions related
to risk management and study design (Fig. 1).
Global agreement is needed to outline the scope of informa-
tion that should be collected for epidemiological studies in nanoma-
terial workers to address the following issues:
• Exposure data measurements and models need to be evaluated
and validated so that they are linkable to worker activities, task
profiles, job titles, job descriptions, and industries on the one hand
and to production processes on the other.
• Potential health concerns need to be identified and biomarkers
of effects need to be assessed for detecting short- and long-term
effects.
• To facilitate global harmonization, not only differences in risk as-
sessment and management but also data protection philosophies
are important while designing epidemiological studies, identify-
ing suitable cohorts, and setting up exposure and health effect
registries.
Feedback loops are needed in each domain of activity. Further-
more, the groups working on harmonizing the exposure, health, and
risk management and study design domains need to be tightly linked,
and considerable cross talk will be needed to ensure a meaningful
and efficient harmonization of methods and approaches.
The road map focuses on occupational health studies of the
nanomaterial workforce. Nevertheless, data collected from such a
harmonized scheme also will be helpful to identify adequate risk
management strategies and to evaluate whether existing protective
measures are efficient. Thus, the data will be useful to industries
using or producing nanomaterials, safety and health experts con-
sulting for these companies, trade unions and politicians who need
to respond to concerned constituents, and governmental and inter-
national bodies dealing with occupational health and safety issues
surrounding nanomaterials.
Exposure to Nanomaterials
Analysis and recording of exposure to nanoparticles are an
important prerequisite for the assessment of their health effects in
workers. Nevertheless, in most instances, this still represents one of
the weakest stages in the risk management process.
A key requirement for all studies is good-quality data for
exposed workers. Measurements need to be feasible and based on
direct factual observations, taking into account the use of protective
equipment and ventilation of facilities and processes that may limit
exposures. Ideally, these exposure studies would be carried out by
an occupational hygienist who is able to link data to activities and
work processes, but in reality, this may not always be possible. A
good nanomaterial exposure assessment should follow these steps:
1. Quantitative and qualitative assessment of potential exposures,
including recording the number of companies, as well as, for ex-
ample, workers handling nanomaterials, quantities of materials
used, handling procedures, and whether nanoparticles are dis-
persed or in powder form during handling.
2. Identification of potential sources of nanoparticle emission and
exposure, noting that “emission sources” are different from “ex-
posure sources”; that is, depending on the risk management mea-
sures in place, working with a source of nanoparticles does not
necessarily correlate with worker exposure to the engineered
nanoparticle of interest. This process should include an aware-
ness of work practices.
3. Agreement on and measurement of possible exposure parameters
according to a harmonized protocol for all sites. This includes
particle metrics and copollutants and contextual information such
as ventilation parameters, room size, protection strategies in use,
and duration of tasks.
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FIGURE 1. Proposed key road-map
elements grouped into three action
domains with relative timing. Con-
siderable cross talk and harmoniza-
tion efforts between these domains
are required to create a global frame-
work for occupational health (OH)
studies. For several elements, nano-
materials pose special challenges re-
lated to their complexity and the as-
sociated uncertainties.
4. Identification of descriptors for job titles, activities, processes, and
industry sectors to build amultidimensional job-activity exposure
matrix for the estimation of personal exposure with statistical
models.
5. Incorporation of the results into industrial, national, or interna-
tional exposure registries.
Before exposure registries can start receiving data, a consen-
sus needs to be reached on the following: the nature and minimal
quantity of exposure data and contextual information required; how
the data should be collected and managed; where it should be stored
(eg, in exposure registries, which may need to be country-specific);
and who is allowed access and under what conditions.13 In addition,
cross talk with health care specialists and epidemiologists is nec-
essary to ensure that the parameters allow for the examination of
potential links between exposure and effect.
Qualitative Assessment of Exposure
Exposure to nanomaterials is plausible at all stages of their life
cycle, from formulation and production to application in products,
use, and disposal. The levels and duration of exposure, as well as
the number of individuals affected, will vary at each stage.14 Ideally,
studies would be based on sufficiently large populations that are
exposed to specific, relevant, well-characterized nanomaterials at
different levels and for different durations. Nevertheless, this is a
real challenge and not easily achievable in today’s nanotechnology
industries because of a range of complex issues, including costs,
identification of workers handling nanomaterials, isolation of effects
from specific manufactured nanomaterials versus those from other
nanomaterials or chemicals involved in the process, and the fact
that identified “high” exposures may lead to immediate corrective
actions under the current precautionary stance being recommended
by regulators and many other stakeholders.15
In reality, although the nanotechnology industries are grow-
ing, the number of nanomaterial workers is still quite small, the ma-
terials handled are heterogeneous, and the exposures are diverse and
continually changing. Information to identify where workers may be
exposed can be derived from investigations of the types of materials
companies are using, the types of workplaces they have, and protec-
tivemeasures in place,16,17 as well as larger, representative surveys to
identify the sectors of industry that are using nanomaterials and that
can provide information about the quantities involved.1 Currently,
research facilities are one of the places where many people seem to
be handling novel nanomaterials.18,19 Nevertheless, universities may
not be ideal places for initial monitoring studies because of highly
varied work activities and the turnover of personnel. Manufactur-
ing sites with fewer short-term changes may be preferable—there is
potential for different processes to give rise to different potential ex-
posures (high vs low) and the best practice to minimize exposure to
chemicals in general is already in place and a culture of safety exists.
Exposure levels also will be industry-specific. An initial pragmatic
solution may be to build on existing field studies, such as those being
conducted by national occupational safety and health institutes (eg,
the US NIOSH)7 or by larger research projects (eg, European Union
Framework 7 studies investigating exposure and protection strategies
in the workplace, of which an overview is given in the NanoSafety
Cluster Compenidum4).
Agreement on Parameters and Measurement of Exposure
There is an ongoing debate about which nanomaterial expo-
sure parameters should be recorded.20 Good-quality data are required
but it is not feasible to take large amounts of measurement equip-
ment into busy workplaces on a routine basis; measurements need to
be ongoing and practical. Furthermore, few validated data on which
physicochemical characteristics make nanomaterials hazardous or
dangerous are available. As this debate continues, pragmatic ap-
proaches to exposure measurements are needed. For research pur-
poses, a detailed analysis of a wide range of parameters, including
mass, particle number, surface charge, surface reactivity, chemical
composition, and characterization by electron microscopy, may be
required.21,22 Nevertheless, inmany other instances (eg, for checking
the efficiency of protective measures), measurement of mass, num-
ber, surface, or charge of particles may be sufficient, regardless of the
size distribution of the nanomaterials. Ideally, any strategy should
rely on practical, personal, and real-time monitoring of exposure to
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nanoparticles in areas where exposure has occurred or is likely to
occur at high concentrations. The best measurement methods are
those that are specific to or highly correlated with the manufactured
nanomaterial of interest.
Around the world, leading research groups are using slightly
different instruments and methods and thus measuring different as-
pects of exposure to particles in the ultrafine or nanoscale range.23 Al-
though themethodological details differ slightly (eg, as demonstrated
by Brouwer20,22), approaches such as those followed in nanoparticle
emission assessment technique (NEAT)24,25 and NANOSH22 can be
integrated to produce a standardized protocol for general nanoscale
materials, but they may not indicate exposure to specific nanomate-
rials. More investigation is needed for these generalized emission-
based approaches to be shown to correlate with more traditional,
filter-based industrial hygiene measurements for specific engineered
nanomaterials.26,27
A series of workshops has been initiated to foster the process
of harmonization and the integration of strategies for exposure mea-
surement, analysis, and storage of data (eg, by NanoImpactNet and
TNO in Europe and by NIOSH in the United States). Supplement-
ing these measurement approaches, exposure also can be assessed
using mathematical models involving key elements, such as the air
dispersion characteristics, the manufactured nanoparticle emission
rate, and the worker’s distance from the emission source. Mecha-
nistic models to estimate exposure to nanoparticles are yet to be
developed; however, concepts and tools for such models have been
proposed28 and can be used to structure the exposure assessment.
For some specific activities, that is, powder handling, a more de-
tailed model has been developed.29 It is likely that in the near future,
further detailed models will be proposed although their calibration
will remain a challenge. Currently, some initiatives are being car-
ried out to harmonize strategies to analyze and report measurement
data to facilitate future pooling and storage of data.23 Such retriev-
able databases will play an important role in the process of model
calibration and validation.
Job-Activity Exposure Models
For the use of exposure models in epidemiological studies, it
is essential that themodels are activity- or task-based and provide ex-
posure distributions to account for within- and between-individual
variation of exposure. Activity- or task-based models can then be
used as building blocks for multidimensional job-activity exposure
matrices for estimating personal exposure. An important condition
for their use is that the description of tasks and activities is unambigu-
ous. The same holds for the description of other input parameters and
contextual information. Another challenge will be to create a com-
prehensive overview of job titles and activities related to exposure
scenarios involving varying levels of exposure. Recent studies sug-
gest that the types of industries where manufactured nanoparticles
are used and the types of exposure scenarios vary considerably.1,30
Because the formation of cohorts for an epidemiological study may
involve combining workers from different companies and possibly
different countries, it is essential that job-activity exposure linkages
are consistent among populations so that they can be included in
pooled epidemiological studies.
An important problem, however, is measuring small numbers
of manufactured nanoparticles against a significant background of
ambient ultrafine particles, where currently only costly off-site anal-
yses allow distinction of particle types.21 Contextual information
about work processes such as kinetic, thermal, and other energies
involved, ventilation systems, and protective equipment can help in
modeling the contributions of task-specific exposure sources and ex-
isting hygiene measures. Here, a set of contextual information may
replace such measurements for the purpose of large epidemiological
studies in which detailed particle assessments at every workplace
would not be feasible.
Incorporation into Exposure Registries
For either short- or longer-term assessment of workers’ health,
good-quality exposure data are required from workplaces where
nanomaterials are routinely used. Thus, studies and exposure char-
acterization campaigns should be promoted, and the information
gathered then needs to be shared broadly and made available to re-
searchers investigating occupational health. Companies should be
encouraged to keep records of work activities that are as detailed as
feasible. Awareness of the need to collect exposure data and establish
exposure registries should be raised as widely as possible and at a
high level in businesses, with senior managers, safety officers, and
occupational health professionals, potentially via continuing profes-
sional development and other continuous education programs and
professional societies.3 These results should then be incorporated
into industrial, national, or international exposure registries. An ap-
proach to creating such registries is discussed later.
Occupational Health Effect Assessment
Workers’ health should be monitored to ensure that their oc-
cupational interaction with nanomaterials does not result in any tem-
porary or permanent harm. To monitor health effects, it is necessary
to identify potential biomarkers and assess their relationship with
exposure, differentiating between subclinical biomarker effects and
health endpoints. Diversity of particle types is a major challenge. Ef-
fect markers may provide a useful strategy to address this issue. One
proposed approach to addressing the diversity of particle types is to
de-emphasize exposure assessment in favor of grouping materials
that produce similar pathways to disease.8
The following steps should be taken for collecting data for
(large-scale) occupational health studies:
1. Identify the pathophysiological mechanisms potentially involved.
Identification can be inspired from the mode of action of tradi-
tional particles and by deducing the likely consequences of novel
physicochemical properties and nano-bio interactions.
2. Once potential pathophysiological mechanisms are identified, it
must be determined which bodily responses and diseases might
be expected and which markers can be used to evaluate and vali-
date their presence. Because potential exposure to manufactured
nanomaterials is new, the initial focus should be on short-term
effects, that is, effects that can be observed after a relatively short
duration of exposure.
3. Some of the long-term effects that need to be assessed will corre-
spond to the accumulation of low-level effects over time, whereas
the onset of others will be delayed such that a relatively short
duration of exposure leads to manifestations of effects only much
later. Markers are needed that are able to detect both types of
long-term effects, and early in the disease’s progression when
corrective actions are still possible.
4. Health data will need to be collected and fed into health surveil-
lance databases. It may be necessary to set up multiple interlinked
databases to account for national differences in health systems and
legislation.
Before any (global) health database can be built, a consensus
needs to be reached about the health endpoints, the markers, and
the methods to be included. The steps toward effective occupational
health data collection, as described earlier, require feedback loops
and regular revision of the parameters needed and which exposure
data can be made available.
The implementation of sound risk management practice
should not be delayed until long-term health studies are completed.
Although long-term effects can be expected and confirmed in re-
search studies only after nanomaterials have been present for some
time, there is an immediate need to take precautionary steps to pre-
vent long-term effects. For example, the recognition of the potential
for diseases with delayed manifestation such as mesothelioma from
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inhalation of some types of carbon nanotubes31,32 implies the need
for immediate and strict precautionary measures. Research will have
to confirm at a later stage that the recommended measures were
indeed sufficient.
In parallel to health effect studies in workers, full assessment
of nanomaterial hazards is required. This will require analysis of all
the bodily systems potentially involved and represents one of the
main toxicological challenges posed by nanomaterials. Much dis-
cussion has taken place about whether the current suite of regulatory
toxicity tests is suitable for nanoparticles. NanoImpactNet, other
European projects, and the WHO Collaborating Centres are empha-
sizing the development and validation of in vitro approaches to test
the health effects of nanoparticles because these reduce the use of
experimental animals. Nevertheless, it must be kept in mind that the
unique aspects of nanomaterials may influence both the experimental
design and outcomes.
Identify Potential Health Concerns and Mechanisms
When reducing the size of materials down to the nanoscale,
physicochemical properties and interactions with biological systems
change. There is considerable uncertainty regarding the health con-
sequences of exposure to these materials. This is partly because of
not only the lack of toxicological data but also a consequence of
the complexity of the nanomaterial-biotic system interaction.33 The
testing and sponsorship program of the Organisation for Economic
Cooperation and Development34 lists more than 30 material proper-
ties as being potentially interesting for study. Nevertheless, combin-
ing the number of physicochemical properties with the number of
health endpoints and testing methods results in an almost unsolvable
task. Thus, to save time and efficiently use limited resources (not just
financial but also workforce and the number of institutions able to
do such extensive testing) prioritization is required.
Prioritization can be based on those characteristics believed
to be most relevant and on effect mechanisms. The particle charac-
teristics scientists most frequently cite as important to defining the
interaction between nanomaterials and biological systems are size,
surface properties, biopersistence (or solubility in biological media),
and morphology.35 Size is a key aspect because small individual par-
ticles may translocate through membranes and tissue barriers, allow-
ing them to travel through the body and reach distal target organs such
as the brain and the liver.36 The aggregation or agglomeration state
of nanoparticles may affect their potential for translocation, whereas
smaller primary particle size is associated with a larger surface area
per unit of mass and thus a greater surface for biological interactions.
Other relevant mechanisms via which nanomaterials are believed to
cause effects are particles acting as transport vehicles,37–39 leading
to the generation of toxic substances such as free radicals and oxida-
tive stress,40–42 and by the fiber paradigm, according to which long
nanotubes are believed to act similar to long asbestos fibers.32,43–45
There is already a wealth of information in the epidemiologi-
cal literature about exposure to “traditional” or “classic” particles and
other (nonengineered) materials that fall within the European Com-
mission’s definition of nanomaterials. These workplace fibers, tradi-
tional nanomaterials, and environmental airborne particulate matter
indicate the types of effects that should be considered, although as
yet unknown effects should not be excluded. Studies of ambient
particles suggest that particle exposure causes oxidative stress and
inflammation, resulting in the release of chemical messengers such
as cytokines, and vasomotor factors with subsequent generalized
inflammation, thrombosis, atherosclerosis, and potentially chronic
obstructive lung disease and pulmonary fibrosis if the target organ is
the lungs.46–48 Studies of workplace fibers suggest that long, bioper-
sistent fibers can lead over time to serious health outcomes such as
mesothelioma, and consequently experts and some national author-
ities recommend precautionary measures similar to those used for
asbestos.15,49,50
Experience from the occupational health monitoring of metal
welders and flame cutters provides the most applicable example of
an available data set, although these workers are not exposed to one
single nanosized material but to heterogeneous mixtures of highly
reactive metal particles (some in the nanoscale size range) and gases.
Reviews of the health effects of these fumes have, however, revealed
few effects beyond modest decreases in lung function, airway irri-
tation, and pulmonary siderosis,51 with effects in the reproductive
systems and central nervous system being inconsistent. The Interna-
tional Agency for Research on Cancer has classified welding fumes
and gases as category 2B: possibly carcinogenic with limited evi-
dence in humans and inadequate evidence in experimental animals.
In contrast to traditional particles, only limited data are avail-
able about novel nanomaterials. A group in Taiwan52 has shown
promising early results for the use of biomarkers of small airway
damage and inflammation, as well as biomarkers of injuries to en-
dothelium and sympathetic nerve activation among workers exposed
to nanoparticles. Another study reported on seven Chinese workers
handling a range of chemicals and nanoparticles who became ill,
with subsequent pathological examinations of lung tissue reveal-
ing evidence of pulmonary inflammation, fibrosis, and foreign-body
granulomas, and nanoparticles were observed in pulmonary epithe-
lial and mesothelial cells.53 Nevertheless, poor occupational hygiene
and the workers’ complex exposures preclude definitive conclusions
about the contribution of nanoparticles to the effects observed.
Strategy to Identify Short- and Long-Term Health Effect
Markers
Once potential endpoints or mechanisms of action have been
identified, markers of effect need to be identified and validated. Bio-
chemical tests or functional parameters to be assessed should be
supported by consistent pathophysiological mechanisms. Attention
could be focused on exposure via inhalation and the skin because
these routes of exposure are better understood for nonnanoscale
chemicals. Pulmonary and cardiovascular diseases (leading to in-
creased morbidity and mortality among vulnerable groups in partic-
ular) have been linked to pollution and levels of ultra-fine particles,
but their use as health endpoints forworkers exposed tomanufactured
nanomaterials have limitations: they are nonspecific (and certainly
not nano-specific), have a high prevalence in the general population,
and share multiple nonoccupational risk factors. Thus, information
about exposure to these other risk factors would also have to be ac-
quired to allow attribution of effects (and it would be only on the level
of worker populations and not individuals). Although these factors
make long-term studies more challenging to conduct and interpret,
they have been used in studies of many occupational diseases.
A variety of other potential short- or long-term effect pa-
rameters have been proposed for a targeted assessment of person-
nel exposed to nanomaterials. These include heart rate variability,
blood-clotting parameters, proinflammatory cytokines, upregulation
of adhesionmolecules or antioxidant capacity, and biomarkers of pul-
monary fibrosis.46,54–56 These biomarkers are increasingly used to as-
sess cardiovascular effects of fine particulate matter, quasi-ultrafine
(ie, particulate matter < 0.25 μm) aerosols, and primary carbon
aerosols derived from traffic-related sources.57–60 These biochemi-
cal parameters have consistent pathophysiological mechanisms that
have been investigated for combustion-derived ultrafine particles and
diesel exhaust particles generated in laboratory settings.61 Although
promising in epidemiological research as putative biomarkers of ef-
fect, these parameters are still not assessable for their predictive value
of health risk at an individual level; they are not routinely applicable
and need to be further validated.
On the basis that the potentially relevant health endpoints
that have been tentatively ascribed to manufactured nanoparticles
are cardiovascular, pulmonary, and inflammatory effects, possible
health monitoring endpoints include the following:
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• Assessment of markers of exposure (eg, presence of chemicals in
the blood or the urine; this can readily be done for chemicals such
as metals-–strictly speaking, not an endpoint).
• Chemical changes in exhaled air or exhaled breath condensate
suggested to reflect not only abnormalities of the airway lining
fluid and lung inflammation62–64 but also potential exposure.65
• Local effects: inflammatory changes, short-term respiratory
changes, respiratory, eye, or skin irritation, depending on the route
of exposure/site of uptake (with special tests to study biopersistent
long fibers such as some forms of carbon nanotubes).
• Systemic effects to confirm cardiovascular changes and inflamma-
tory mechanisms: heart-rate variability, platelet aggregation, and
other prothrombotic effects, as well as cytokines and differential
blood cell counts.54,66
• Medical tests for early detection of health effects at a preclinical
stage (eg, clinically validated biologicalmarkers of cardiovascular,
hepatic, renal, hematological, or respiratory dysfunctions).
We do not yet know whether or how such health effects may
differ between chemically or structurally different particles at the
nanoscale. To date, biomarkers of exposure cannot be adequately
developed because of the lack of consistent toxicokinetic studies of
nanomaterials, which may be partly related to the enormous vari-
ability of surface properties for each type of nanomaterial and even
between batches of the same material. Nevertheless, it is likely that
traditional biomarkers of exposure (eg, mass quantification in serum
or urine) will be more feasible for nanoscale metals than for car-
bonaceous nanomaterials. At present, it is unknown whether manu-
factured nanoparticles in general, and carbon nanotubes in particular,
can exacerbate preexisting medical conditions or increase the sus-
ceptibility to certain diseases.
Occupational Health Databases
Health data collection should be tightly linked to exposure as-
sessment. At a minimum, health data collection should be accompa-
nied by a general exposure assessment at workplaces with identified
risk potential. An occupational health database will need to allow the
identification of exposed individuals, worker populations, or both.
Ideally, such a database would be held at a centralized data collection
sitewith extended health screening at specific nanomaterial facilities.
In addition to this basic data collection, targeted research studies will
be needed with detailed exposure assessment and extended health
effects monitoring, including mechanistic studies of the effects of
nanomaterials. As for exposure, companies should be encouraged to
keep records, awareness about the need for data collection should be
raised, and the data should be incorporated into industry, national,
or international health registries. It would be useful if the databases
can be linked to existing databases such as national or international
registries of death and cancer.
Harmonized Study Designs and Data
Collection Strategies
The success of epidemiological studies for quantitative risk
assessment depends on the quality of available exposure and health
response data. To achieve a coherent approach that leads to valid
conclusions, data collection needs to be defined in anticipation of
future (ideally prospective) studies that will pool and compare dif-
ferent situations worldwide. Over the coming years, the following
points need to be addressed:
• Risk assessment and management cultures in different industrial
sectors and countries need to be identified.
• Data collection strategies, data protection philosophies, and the
associated legal systems of different countries need to be assessed
and strategies for dealing with them defined.
• The most suitable epidemiological designs for different purposes
need to be identified.
• Exposure and health registries need to be established that can
link to health surveillance systems or epidemiological research
projects.
It is unlikely that a single, global project on this scale could
be set up to follow workers exposed to nanomaterials. Nevertheless,
a more modest approach with harmonized exposure and health reg-
istries could be established, recording details of workers’ activities,
available information about exposure levels, the nanomaterials han-
dled, and health condition. Ideally, workers’ samples (eg, blood and
urine) would be stored for later analysis asmore potential biomarkers
of effect and exposure become available.
Identify Ethical, Cultural, and Regional Differences
Any global data collection strategy needs to account for
regional differences in existing technologies, exposure protection
strategies, safety culture, data protection philosophies, and ethical
aspects.67 These challenges are superimposed on the challenges and
data needs for the conceptual models described earlier. For each of
the recognized data-collection needs, potential challenges for col-
lecting (in the sense of being able to obtain) and defining (in the
sense of using terminology that is free of sensitive connotations)
such data need to be identified. Differences in data protection laws
might pose challenges not only to the collection68 but also to the
pooling of data across frontiers. Usually, data can be used only for
a predefined purpose, and subjects’ identities must not be revealed.
In some countries, individuals can request that their data be with-
drawn at any moment during the study, often there is an expiration
date relating how long data can be stored, and data may be shared
only with researchers located in countries that have at least the same
regulation of data protection.
All of these challenges need to be described and addressed
in a strategy on how to overcome the differences and gaps when
defining the data needed for collection. Thus, information about
cultural and regional differences should be an integral part of the
recommendations for a globally harmonized data collection strategy.
WHO Collaborating Centres and the Organization for Economic
Cooperation and Development may have an important role to play in
the collection of such data about cultural and regional differences.
Define Epidemiological Designs
Well-conducted epidemiological studies are an important
source of information to risk assessment because they provide di-
rectly relevant human data. Epidemiological studies face challenges
due to uncertainties in exposure measurements, dose to the tar-
get organ, and health effects resulting from the interaction of cells
with nanomaterials. Nevertheless, examples exist (eg, radon-exposed
miners69 and asbestos-exposed textile workers70) in which prospec-
tive cohort studies have produced data that form the basis of quanti-
tative risk assessments.
Currently, the number of workers facing a potential exposure
to manufactured nanomaterials is not known. Major challenges in
conducting prospective cohort studies of nanomaterial workers in-
clude developing a large cohort size and the long periods of time
required to draw firm conclusions regarding chronic health effects.
In the interim, small-scale studies of 50 to 100 workers could be
conducted within the next 5 years to assess biomarkers of exposure
or of early effect.9
Although there is currently no firm basis for the recommen-
dation of targeted nano-specific occupational health surveillance for
most manufactured nanomaterials, this should not be a reason for
paralysis or inactivity. There are clear knowledge gaps and achiev-
able recommendations can be made:
1. General health surveillance should target those working with
nanomaterials where exposure is likely (eg, processes that are not
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contained), and the systems for recording the processes and types
of nanomaterials used by the workers should be improved.
2. Workplaces should apply measures to control exposure, contain-
ing particle emissions, and deploying personal protective equip-
ment for workers when appropriate if potential exposure to nano-
materials cannot be excluded. The measure should be recorded,
ideally in a standardized reporting format, during occupational
health studies.
3. Simple questionnaires could be used for self-reporting symptoms
so that focused studies can be undertaken for different types of
nanomaterials and industries.
4. Individual cases of ill health in those working with nanomaterials
should be scrutinized to assess whether nanomaterials are a likely
attributable source of the ill health.
5. Improved sharing of knowledge should be encouraged at national
and international levels through occupational health-reporting
networks.
6. Simple nanomaterial measurement techniques are required that
can be applied under most occupational circumstances without
advanced technical knowledge.
7. Use should be made of biological monitoring (where applicable).
Overall, there is a clear need to gather experimental, clinical,
and epidemiological data to characterize the relationship between
exposure and health outcomes and provide a basis on which to build
and explore the effectiveness of preventative measures.
Health Surveillance and Setting Up Registries
The rapid development of exposure registrieswill help provide
data for the epidemiological studies of the future.3,71 Nevertheless,
there are currently no validatedmethods for healthmonitoring and re-
porting that are specific to nanoparticles, but existing approaches for
nonnanoscale substances could be adapted. In the United Kingdom,
occupational health reporting systems have been developed, but they
rely on reporting (sometimes self-reporting) of adverse outcomes,
and they rarely record information about exposure levels. Further-
more, if effective preventive approaches are adopted in workplaces
handling nanomaterials, the number of expected adverse outcomes
could be very small or even nonexistent. In France, basic information
about workers’ health status is already being collected via manda-
tory occupational health surveillance, and this will be available in
the future for retrospective studies.10 The approach recommended by
NIOSH in the United States is to consider the hazard and exposure
levels of nanomaterials when making a decision about whether to
use routine medical surveillance.72
Historically, in occupational medicine, the practice of health
surveillance has represented the final step in a process based on
the integration of both experimental and epidemiological studies
that identify the hazards and are supported by the implementation
of occupational exposure limits. Medical surveillance requires at
least a qualitative risk assessment and can be implemented when a
residual risk exists and when the target population has been clearly
identified.72 One major issue is the correct classification of expo-
sure situations and linking them to the medical records. Currently,
validated or even calibrated exposure models are lacking; however,
the application of such models for estimating the exposure of indi-
viduals will be hampered by the lack of indications of within- or
between-individual (worker) variances.
Although there are no specifically validated methods for the
risk assessment of nanomaterials in the workplace, the occupational
safety community may be underutilizing its existing knowledge of
hazard and exposure control of ionizing radiation, biological agents,
pharmaceuticals, nuisance dusts, and pollution.73 With technology
developing so rapidly, it will be necessary to make continual re-
assessments and reevaluations of the risks to workers’ health and
safety from nanotechnologies and nanomaterials in particular. It is
suggested that existing regulations can address the emerging issues
and potential hazards presented by nanoparticles in the workplace,
and although some disagree with this view, guidance and codes of
conduct have been produced by different organizations (eg, European
Commission, UK’s Health and Safety Executive,15 and NIOSH74).
Although incomplete, the body of toxicological evidence on man-
ufactured nanomaterials suggests that occupational hygienists and
health and safety professionals should recommend precautionary
management measures in the workplace, including in research labo-
ratories handling nanoparticles.
Risk management of nanomaterials in the workplace would
involve recognition of potential worker exposure and the implemen-
tation of measures to reduce or minimize it75 Occupational health
surveillance and epidemiological research can support the risk man-
agement process not only by assessing whether health effects can be
found at levels believed to be safe but also by identifying the risks
to workers where the exposure is insufficiently controlled.3 Thus,
health surveillance and epidemiology are important tools to ensure
workers’ health. Medical screening constitutes just one part of a
complete health and safety management program. National Institute
for Occupational Safety and Health has published interim guidance
on medical screening for workers handling nanomaterials,72 which
discusses the value of medical screening for asymptomatic workers.
A second NIOSH guidance document50 describes the need for med-
ical surveillance for carbon nanotubes, which demonstrate a specific
hazard in toxicological studies.
Harmonization of Studies
To enable the harmonization of studies, preparatory steps
such as the establishment of exposure and health effect registries
may be needed. Occupational exposure and health registries have
been used in public health for more than 50 years and are es-
pecially useful when the risks to workers are not well defined.
Recently, the Dutch Health Council and the Social and Eco-
nomic Council of the Netherlands strongly recommended the es-
tablishment of an early warning system and exposure registries for
nanomaterial workers (http://www.gezondheidsraad.nl/sites/default/
files/Nanotechnologie2.pdf , http://www.gezondheidsraad.nl/sites/
default/files/200818.pdf , http://www.ser.nl/∼/media/DB Adviezen/
2000 2009/2009/b27741.ashx).
We propose generation of an international framework under
which such registries could be developed with a harmonized format
and interlinked across Europe and globally. The proposed actions
and related objectives are shown in Table 2.
Development of such registries would ideally occur on an
international scale to increase the numbers of workers recruited,
although national views and regulations about data gathering and
security may complicate this. These problems could be avoided by
establishing national registries that collaborate internationally.
Such a system for international surveillance can be set up in
analogy to initiatives done for assessment of background exposure
in the normal population. Indeed, within the frame of the FP7 EU
project COPHES and the Life+ supported project DEMOCOPHES,
a strategy for harmonized human biomonitoring in 17 EU countries
is currently worked out. In parallel with what was done there, also for
occupational exposure to nanomaterials, a pilot monitoring program
can be worked out to start organizing registries, measurements, or
both, starting on a limited scale. The study should be coordinated
and steered by a limited group of a few partners who prepare the
pilot study. In this context, it would be good to include partners of
industry and occupational associations in this steering group. If there
are enough resources, other participants can join and should be fully
supported by providing all necessary (technical) advice and training.
To obtainwide acceptance of and support for such approaches,
communication will be a very important element. This communica-
tion needs to reach workers, managers, policymakers, and research
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TABLE 2. Central Issues for Study of Workers’ Exposure and Health
Actions Objectives
Collect, collate, analyze, and evaluate existing accessible data on exposure
and contextual information, including activity-based exposure profiles
regarding their potential use in cohort studies and protection strategies.
Review of existing exposure data to identify which risk management
measures are most effective in reducing potential exposure,
including during nonroutine operations or accidents.
Identify existing descriptors for job titles, activities, processes, and
industrial sectors, and subsequently build a multidimensional
job-activity exposure matrix for the estimation of personal exposure.
Identify and critically evaluate candidate biomarkers of effect and exposure
to nanomaterials.
Evaluate practical issues for use of biomarkers in epidemiological studies
and health registries of nanomaterial workers.
Develop models to link job activities to potential exposure to allow
evaluating the effect of current risk management practices on
exposure levels. Test the feasibility of using the proposed matrices in
epidemiological studies.
Evaluate and select candidate biomarkers to contribute to improved
methods for health impact assessment, particularly for monitoring
early health effects in exposed populations.
Assess existing epidemiological studies as well as the most critical issues
in designing epidemiological studies in nanomaterial workers.
Test feasibility of the proposed study designs using existing data formats.
Review and evaluate existing and emerging tools for early assessment
and management of risks among workers exposed to nanoparticles, and
provide guidance for their harmonization and improvement.
Develop guidance for exposure and health registration to be used by small
and medium enterprises.
Outline the needs and possibilities for building occupational
epidemiological studies for workers dealing with nanomaterials.
To obtain harmonized exposure and health effect monitoring that
allows a better evaluation of the various existing risk management
tools. It also may eventually help identifying potential risky materials
and strategies for managing these risks in a conservative manner.
funding agencies. It was recommended that communication about
nanomaterial risks should adopt established concepts of risk percep-
tion and risk communication strategies.76
Check Appropriateness of Screening Strategies
When hazard data are absent (as with many nanomaterials),
the issue is whether it is possible or informative to initiate spe-
cific health surveillance for nanotechnology workers.71 Unnecessary
health surveillance itself can be associated with risks if it leads to
incorrect diagnoses, uncertain interpretation, and the perception that
work may not be “safe” for workers. Criteria of appropriateness
should, therefore, be assessed; that is, any screening strategy for a
worker’s health should be justified on the basis that (1) finding amed-
ical condition at an earlier stage significantly improves the potential
outcome compared with a situation with no screening; (2) especially
in the case of chronic diseases, it helps reduce the population’s ex-
posure to a level that prevents the development of these early stages
of disease; or (3) the screening program is used as part of a wider
strategy to ensure effective exposure control.
A range of factors needs to be considered to determine
whether implementing health surveillance in the workplace is ap-
propriate. Among the existing criteria are assessment of the burden
of suffering (which the precautionary approach aims to prevent), the
accuracy and reliability of current test methods, the effectiveness of
early detection in the absence of clear correlations to health end-
points from manufactured nanomaterials, and an assessment of the
benefits versus any harm resulting from the screening itself. On the
basis of these criteria, the known risks associated with some screen-
ing methods (eg, chest radiography or computed tomography) would
have to be outweighed by the benefits, such as implementation of
workplace risk management measures or preventative health inter-
ventions, before such a recommendation could be made. Routine
screening has to be justified on the basis of a sufficient likelihood
of the expected exposure to manufactured nanomaterials causing
the condition in question; the absence of any indication of a risk
attributable to nanoparticle exposure precludes conclusions on this
point at present.
CONCLUSIONS AND RECOMMENDATIONS
To best understand and control the health and exposure risks of
workers dealing with manufactured nanomaterials, studies of groups
and cohorts of those workers are necessary. At the moment, the nec-
essary framework conditions to conduct such studies are not in place.
To provide a coherent approach and make future epidemiological re-
search a reality, a well-defined framework is needed for the careful
choice of materials, characterization of exposure, identification of
study populations, definition of health endpoints, and evaluation of
the appropriateness of study designs. Particularly needed are
• A basis for prioritizing which engineered nanomaterials merit in-
vestigation (eg, on the basis of toxicological or inferential studies).
• A consistent, evidence-based set of job titles and task-based ex-
posure profiles for epidemiological studies (informed by actual
individual workplace assessments).
• A method for linking industry, company, and job descriptors to
exposure and consistent exposuremetrics; this will need to provide
recommendations on the type and format of data to be collected
and how it can be interlinked so that future studies can use the data
for developing exposure estimates for large cohorts of workers.
• Criteria for potentially useful biomarkers and (pre)clinical pa-
rameters for epidemiological studies about workers in small and
medium enterprises and transnational companies. Recommenda-
tions on the feasibility of human population studies based on these
biomarkers.
• Recommendations on the requirements for harmonized ap-
proaches for human biomonitoring and health effect studies tai-
lored to nanomaterial workers.
• Recommendations for harmonization and the improvement of
tools for early assessment and management of risks and exposure
registration. These should be made available to relevant stake-
holders, including small and medium enterprises, along the global
value chain.
For either short- or longer-term assessment of worker health,
good-quality exposure data are required from workplaces where
nanomaterials are routinely used, andmethods for collection of expo-
sure data should be tested, validated, and agreed upon internationally
with some urgency. Concomitantly, field studies and exposure char-
acterization campaigns should be promoted and information shared
broadly. Companies should be encouraged to keep records of work
activities that are as detailed as feasible, and, if possible, full use
should be made of simple sensors, such as particle counters (recog-
nizing that these are not at all specific for the manufactured nano-
material of interest). Awareness of potential hazards and the need
to collect exposure data and establish exposure registries should be
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raised as widely as possible, potentially at a high level in businesses,
with senior managers, safety officers, and occupational health pro-
fessionals, potentially via continuing professional development and
other programs of continuing education.
Although at present no nano-specific screening procedure ex-
ists for the medical surveillance of workers potentially exposed to
nanoparticles, periodic general medical examinations are to be rec-
ommended, preferably on the basis of noninvasive procedures. In-
creasing general health surveillance for these workers could lead to
an earlier recognition of adverse effects and information about which
symptoms should be observed in other similarly exposed workers.
This might also lead to informative individual index cases being
identified.
There is an urgent need for further toxicological evaluation
and physicochemical characterization of all the types of nanoma-
terials currently handled in workplaces, and a determination of the
relationship between particle characteristics and health effects so as
to facilitate prediction of the effects of newmaterials, and to identify
themost important exposure characteristics to be assessed. Biomark-
ers of exposure and health effects also are required, and novel, ideally
point-of-care, detection techniques need to be explored for assessing
those exposures, for example, via determination of particle numbers
or proinflammatory cytokines in exhaled breath condensate.
In spite of the advances in establishing a conceptual frame-
work leading to a higher degree of worker protection, epidemiolog-
ical studies of workers potentially exposed to manufactured nano-
materials will be difficult to conduct for both ethical and practical
reasons. These include the heterogeneity of nanomaterials used in
occupational settings, the overlap in exposure between combustion-
or pyrolysis-derived ultrafine particles and manufactured nanoparti-
cles, the lack of standardized exposure metrics, the long time frame
required to develop informative exposure histories, and the inter-
national cultural differences related to surveillance systems, data
recording and storage, and data protection. Further issues include
how to distinguish health effects that may arise from exposure to
nanomaterials from those due to exposure to other workplace haz-
ards and potential toxicants and the effects of multiple exposures
and confounding factors, such as smoking and underlying health
conditions.
The proposed road map addresses a joint strategy and the
flow of actions needed to achieve these goals. Such a joint strat-
egy will ensure that the costs of action are not disproportionate to
the potential benefits and, importantly, that the strategy will be prag-
matic and practical. The discussion about the benefits and challenges
associated with the different potential approaches for occupational
health surveillance and epidemiological studies for workers exposed
to nanomaterials has only just begun. Nevertheless, results from such
studies are needed for the assessment of nanomaterial workers’ risk
and for evaluation of exposure controls.
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